Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The present study is proposed to evaluate the efficacy and safety of single doses of Diclofenac HPBCD subcutaneous (s.c.) (25 mg/1 ml and 50 mg/1 ml) in the treatment of acute moderate-to-severe pain after dental impaction surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: IBSA Institut Biochimique SA
• Treatments: Diclofenac

Criteria

Inclusion Criteria:

• Patients undergoing surgical extraction of a single fully or partially impacted mandibular 3rd molar requiring bone removal.

• Patients experiencing moderate to severe post-operative pain within 6 hours from end of surgery.

• Pre-operative laboratory tests in the reference ranges or without clinically significant abnormalities as judged by the Investigator.

Exclusion Criteria:

• Surgery performed under general anaesthesia, or sedation.

• Complications occurring during the surgical procedure or in the period before randomisation as judged by the investigator.

• Acute local or systemic infection at the time of surgery that could confound the post-surgical evaluation.

• Patients with clinical signs of gastritis, gastro-duodenal ulcer, GI bleeding. Other GI disturbances or disease that in the opinion of the investigator could be negatively affected by the administration of NSAIDs.

• Clinical signs or history of coagulation disorders that could be negatively affected by NSAIDs administration.

• Hepatic or renal impairment.

• Patients with significant cardiac impairment, history of cerebrovascular disease, history or peripheral arterial disease, uncontrolled hypertension.

• Hypersensitivity to diclofenac or other NSAIDs or to one of the study medication components.

• Patients under chronic treatment with topical or systemic analgesics/NSAIDs.

• Patients under treatment with any medication that may affect the treatment efficacy evaluation.

• Patients under treatment with any medication whose concomitant use may be susceptible to interactions with diclofenac or may affect safety.